Evidence map›Paper›PMID 24225757›Full record

ArticleAmerican journal of clinical pathology2013

Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks.

Catherine C Godfrey, Pamela M Michelow, Mandana Godard, Vikrant V Sahasrabuddhe, Janice Darden, Cynthia S Firnhaber, Neal T Wetherall, James Bremer, Robert W Coombs, Timothy Wilkin and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of clinical pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Patient Safety Monitoring in International Laboratories.MLO: medical laboratory observer · 2021
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 2 countries.

Catherine C GodfreyNational Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700 B Rockledge Dr, Bethesda MD 20892; Cgodfrey@niaid.nih.gov.
Pamela M Michelow
Mandana Godard
Vikrant V Sahasrabuddhe
Janice Darden
Cynthia S Firnhaber
Neal T Wetherall
James Bremer
Robert W Coombs
Timothy Wilkin
A5282 Study Team
Cornell University · USHenry M. Jackson Foundation · USJohns Hopkins University · USNational Health Laboratory Service · ZANational Institutes of Health · USRush University Medical Center · USSocial and Scientific Systems (United States) · USUniversity of the Witwatersrand · ZAUniversity of Washington · USVanderbilt University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6M
Vanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU Y18 SupplementUM1AI069456 · NIAID · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2012 to 2026
$29.4M
NIAID NIH HHS AI27757NIAID NIH HHS AI38858NIAID NIH HHS HHSN272200800014CNIAID NIH HHS HHSN272201200023CNIAID NIH HHS HHSN272201300004CNIAID NIH HHS P30 AI027757NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069456NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069463-07
6 · The paper itself

Abstract

objectivesTo evaluate an external quality assurance (EQA) program for the laboratory diagnosis of human papillomavirus (HPV) disease that was established to improve international research capability within the Division of AIDS at the National Institute of Allergy and Infectious Disease-supported Adult AIDS Clinical Trials Group network.

methodsA three-component EQA scheme was devised comprising assessments of diagnostic accuracy of cytotechnologists and pathologists using available EQA panels, review of quality and accuracy of clinical slides from local sites by an outside expert, and HPV DNA detection using a commercially available HPV test kit.

resultsSeven laboratories and 17 pathologists in Africa, India, and South America participated. EQA scores were suboptimal for EQA proficiency testing panels in three of seven laboratories. There was good agreement between the local laboratory and the central reader 70% of the time (90% confidence interval, 42%-98%). Performance on the College of American Pathologists' HPV DNA testing panel was successful in all laboratories tested.

conclusionsThe prequalifying EQA round identified correctable issues that will improve the laboratory diagnosis of HPV-related cervical disease at the participating international study sites and will provide a mechanism for ongoing education and continuous quality improvement.

Indexed as

Acquired Immunodeficiency SyndromeClinical Trials, Phase II as TopicFemaleHuman Papillomavirus DNA TestsHumansLaboratoriesMass ScreeningNational Institutes of Health (U.S.)Papillomavirus InfectionsPathologyQuality Assurance, Health CareRandomized Controlled Trials as TopicUnited StatesUterine Cervical NeoplasmsCervical cytologyCervical pathologyEQAExternal quality assuranceHistopathologyHPVHPV DNA testing

Identifiers

PMID24225757
PMCPMC4017200
OpenAlexW2156073713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.